secwatch.observer — SEC 8-K summary
======================================

Issuer:     Estrella Immunopharma, Inc. (ESLA)
CIK:        0001844417
Form:       8-K
Filed at:   2025-05-29T23:59:59+00:00
Accession:  0001213900-25-048597
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Estrella Immunopharma doses first patient in STARLIGHT-1 second cohort for EB103 in NHL
--------------------------------------------------------------------------------

- First patient dosed in second cohort of Phase I/II STARLIGHT-1 trial evaluating EB103 at higher dose.
- No dose-limiting toxicities or treatment-related serious adverse events observed in first cohort.
- Complete response reported in first cohort; trial targets advanced B-cell non-Hodgkin's lymphomas.
- CEO Cheng Liu highlights potential for HIV-associated and CNS lymphoma patients currently excluded from CAR-T.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1844417/000121390025048597/0001213900-25-048597-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1844417/000121390025048597/ea0243703-8k_estrella.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-048597

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer